Cytopoint^® Success

This study was an independent, real-world, retrospective analysis of medical records of dogs with allergic dermatitis treated with Cytopoint^® from November 2015 to October 2016. Treatment success for owner-assessed pruritus was empirically defined as a ≥2 cm reduction in pruritus visual analog scale (PVAS) from baseline. The 135 dogs in this study included 80 with atopic dermatitis (7 seasonal, 73 nonseasonal), 10 with concurrent food allergy and atopic dermatitis, 45 with allergic dermatitis of undetermined cause, 3 lost to follow-up and 0 flea-allergic dogs. This study was completed at Colorado State University in Fort Collins, Colorado.

This study was an independent, real-world, retrospective analysis of medical records of dogs with allergic dermatitis treated with Cytopoint^® from November 2015 to October 2016. Treatment success for owner-assessed pruritus was empirically defined as a ≥2 cm reduction in pruritus visual analog scale (PVAS) from baseline. The 135 dogs in this study included 80 with atopic dermatitis (7 seasonal, 73 nonseasonal), 10 with concurrent food allergy and atopic dermatitis, 45 with allergic dermatitis of undetermined cause, 3 lost to follow-up and 0 flea-allergic dogs. This study was completed at Colorado State University in Fort Collins, Colorado.

This was a multicenter, prospective, open observational phase IV study with an objective of understanding the efficacy of 3 monthly doses of Cytopoint^® in dogs with atopic dermatitis (n=110). Dogs were evaluated weekly for pruritus and monthly for clinical signs of atopic dermatitis to understand the benefit of consecutive monthly dosing. Single doses were administered on study Day 0. Dogs who achieved a satisfactory result left the study, while dogs who had not achieved a satisfactory result were administered a second injection of Cytopoint at label doses. This was repeated with a new evaluation at Day 60, and doses continued for dogs who had not achieved treatment success.

Treatment success was defined as achieving a 20 mm reduction in pruritus visual analog scale (PVAS) from baseline. Inclusion and exclusion criteria were intended to ensure enrollment of dogs with atopic dermatitis but without other concurrent disease or pharmaceutical treatments that could confound the study. Dogs had a documented history of nonseasonal atopic dermatitis or seasonal atopic dermatitis where prior history supported disease preferences for at least 4 months following initiation of treatment.